Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-1,774.4%-644pp-1,130.6%+488pp-1,618.5%-458pp-1,160.8%+64.9pp-1,225.8%-128pp
Net margin-1,738.4%-623pp-1,115.3%+468pp-1,583.7%
Returns
Return on equity-97.3%-28.8pp-68.5%-3.5pp-64.9%
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.0×
Liquidity
Current ratio14×+1.8×12.2×+1.8×10.5×-2.0×12.5×+7.1×5.4×-0.1×
Leverage
Debt-to-equity0.3×0.0×0.3×0.0×0.3×+0.1×0.2×-0.9×1.1×+0.2×
Per Share
Book value per share$0.58-25.2%$0.77+24.6%$0.62-25.7%$0.83+308%$0.20-28.5%
Valuation
Market capitalization$1.28B-14.8%$1.51B+68.9%$892.04M+43.9%$619.83M+118%$284.95M-19.6%
Price / sales171.9×+17.7×154.2×+12.8×141.4×+64.8×76.5×+37.1×39.4×-3.1×
Price / book6.1×0.0×6.1×+2.0×4.1×+1.6×2.5×-2.7×5.2×+0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Taysha Gene Therapies, Inc.'s ratios come from?
Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.